Cat. No.
MABL-1131
Application
therapeutic, Block, ELISA
Isotype
Engineer antibody
Species Reactivity
Human
Clone No.
7C10
From
Recombinant Antibody
Specificity
This antibody binds human CD80 and inhibits the B7.1:CD28 pathway.
Alternative Names
B7.1; CD28L; CD28LG; B7-1; B7; BB1; B7/BB1;T-lymphocyte activation antigen CD80; Activation B7-1 antigen; CTLA-4 counter-receptor B7.1; CTLA4L; CTLA-4L
UniProt
P33681
Immunogen
This antibody was generated by immunization of cynomolgus monkeys with human B7.1 antigen.
Application Notes
This antibody can be used for identification of human B7.1 antigen and is capable of inhibiting the binding of B7.1 to CD28, however it does not block the binding of B7.1 to CTLA-4. This antibody further inhibits the production of IL-2. Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signaling. The binding of the antibody to soluble B7.1 was tested using ELISA. This antibody tested positive for binding to human C1q protein. This antibody is reported to cause keratinocyte hyperproliferation and decrease in psoriasis by inhibiting the B7:CD28 pathway. This antibody is further reported to be useful for the treatment of intestinal inflammation and rheumatoid arthritis.
Antibody First Published
Note on publication
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.
